Showing results (251-260 of 319) with videos related to
Sort By:
Pageof 32
International Journal of Radiation Oncology, Biology, Physics|December 10, 2013
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trialPrajnan Das, Cathy Eng, Miguel A Rodriguez-Bigas, et al.Cancer Medicine|June 16, 2021
Surgical resection and survival outcomes in metastatic young adult colorectal cancer patientsNina D Arhin, Chan Shen, Christina E Bailey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2014
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancerEric Van Cutsem, Cathy Eng, Elzbieta Nowara, et al.Translational Lung Cancer Research|March 14, 2022
Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancerJie Dai, Xinsheng Zhu, Dianke Li, et al.Cancer|May 19, 2017
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapyJessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, et al.Oncotarget|August 20, 2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentinMichael J Overman, Van Morris, Helen Moinova, et al.Journal of Gastrointestinal Oncology|August 9, 2019
Medical record review of transition to lanreotide following octreotide for neuroendocrine tumorsMuhammad Wasif Saif, Rohan Parikh, David Ray, et al.Annals of Surgical Oncology|September 23, 2017
Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free SurvivalCallisia N Clarke, Michael S Lee, Wei Wei, et al.Lancet (London, England)|October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trialJ Randolph Hecht, Young Suk Park, Josep Tabernero, et al.Journal of the National Cancer Institute|August 3, 2023
NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancerHagen F Kennecke, Rebecca Auer, May Cho, et al.Pageof 32